Introduction and Objective: Older adults with obesity are at increased risk for metabolic dysfunction and type 2 diabetes. Aging and excess adiposity promote the accumulation of senescent cells in adipose tissue (AT), contributing to chronic inflammation and impaired adipocyte function. Lifestyle interventions including weight loss and exercise improve metabolic health in older adults with obesity; […]
Read MoreAuthor: sugaradmin
2812-LB: Long-Term Impact of Early Oral Antidiabetic Therapy on Insulin Secretion Phases in Individuals with Prediabetes (PreDM): Insights from Hyperglycemic Clamp Studies
by sugaradmin
Introduction and Objective: Antidiabetic agents differ in their mechanisms of action and can exert distinct long-term effects on β-cell function (BCF). Hyperglycemic clamp studies (HC) enable detailed assessment of first- and second-phase insulin secretion (ISecr), yet comparative longitudinal data across drug classes among individuals with PreDM remains limited.Methods: Sixty PreDM subjects were studied and treated […]
Read More1364-P: Exercise with PACTAID Maintains Time in Range and Reduces Hypoglycemia in Adults with Type 1 Diabetes Using Automated Insulin Delivery
by sugaradmin
Introduction and Objective: To evaluate the feasibility and effectiveness of the PACTAID application in reducing hypoglycemia during and after exercise in adults with type 1 diabetes (T1D) using the Tandem Control-IQ system.Methods: In this prospective study, adults with T1D on Control-IQ completed 20 exercise sessions with PACTAID support. Baseline and end-of-study assessments included ambulatory blood […]
Read More1036-OR: ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA)
by sugaradmin
Introduction and Objective: Food insecurity is a key risk factor for severe hypoglycemia among insulin users. Whether this extends to non-insulin-treated secretagogue users remains unexamined, despite widespread prescribing of these agents, particularly in cost-sensitive contexts. We analyzed data from the iNPHORM study to address this gap.Methods: Adults (≥18 years) with type 2 diabetes (T2D) on […]
Read More2978-LB: Annual Prevalence of Diabetic Ketoacidosis and Severe Hypoglycemia in Type 2 Diabetes
by sugaradmin
Introduction and Objective: Diabetic ketoacidosis (DKA) and severe hypoglycemia (SH) require costly, high-intensity acute care. Recent trends in type 2 diabetes (T2D) are not well described. We estimated annual prevalence of DKA and SH requiring emergency department (ED) or inpatient (IP) care among people with T2D.Methods: We analyzed Inovalon Insights claims (2017-2024) from Commercial, Managed […]
Read More2346-P: Access to GLP-1 Receptor Agonists (GLP-1RA) and Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) for Type 2 Diabetes Mellitus (T2DM) by Sociodemographic Factors in a Large Integrated Health System
by sugaradmin
Introduction and Objective: GLP-1 RAs and SGLT-2i have transformed T2DM management by improving glycemic control, promoting weight loss, and reducing the risk of cardiometabolic-renal disease. This study’s aim was to assess real world prescribing patterns of GLP-1 RAs and SGLT-2i within a large health care system and assess variations across sociodemographic groups.Methods: A retrospective analysis […]
Read More2351-P: Assessment of Phenotypic Clustering of Incident and Prevalent Type 2 Diabetes: A MESA Pilot Study in the Definition, Etiology, Function: Integration to Enhance Type 2 Diabetes Treatment (DEFINE-Type 2 Diabetes) Consortium
by sugaradmin
Introduction and Objective: Phenotypic clustering of T2D into aging-related (MARD), obesity-related (MOD), insulin-deficient (SIDD), and insulin-resistant (SIRD) subgroups may capture heterogeneity, but performance and stability in diverse populations are uncertain.Methods: We performed established k-means clustering models in 871 prevalent and 462 incident T2D cases with data for age at onset, BMI, HbA1c, HOMA2-IR, and HOMA2-β […]
Read More2110-P: Risk Factors for Elevated Blood Pressure in Children with Type 1 Diabetes: Evidence from a Population-Based EHR Cohort and a Pediatric Biobank
by sugaradmin
Introduction and Objective: Elevated blood pressure (BP) is a common but underrecognized contributor to vascular complications in children with type 1 diabetes (T1D). We aimed to characterize BP patterns and kidney function trajectories in pediatric T1D and to identify clinical, immune, and genetic predictors of elevated BP.Methods: We examined longitudinal patterns of BP and eGFR […]
Read More2614-P: Understanding the Lived Experiences of Dosing Practices among People Living with Obesity (PwO) Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Weight Loss (WL): A U.S. Qualitative Study
by sugaradmin
Introduction and Objective: GLP-1 RAs are increasingly used for WL, yet little is known about how PwO experience and personalize treatment in everyday life. This mixed-method study aimed to elucidate the dynamics shaping treatment experiences and dosing practices of PwO using GLP-1 RA in the US.Methods: Public user-generated content from Reddit (N>250,000 posts) and YouTube […]
Read More2609-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
by sugaradmin
Introduction and Objective: HDM1002, a novel, orally bioavailable non-peptide full agonist of GLP-1RA, demonstrated promising weight loss in phase 1 trial. This phase 2 study evaluated the efficacy and safety of HDM1002 in Chinese overweight and obese adults without diabetes mellitus.Methods: In this randomized, double-blind, placebo-controlled, multicenter study (NCT06500299), 185 participants (pts) (BMI 28-40 kg/m²) […]
Read More